Clinical trials evaluating combinations of targeted agents with bortezomib, the first-in-class
proteasome inhibitor, have been initiated, with the objective of enhancing its single agent …

The mammalian target of rapamycin (mTOR) pathway regulates translation of key proteins
that contribute to the pathogenesis of advanced hematologic malignancies. Inhibitors of …

The proteasome has been regarded as a major target for antitumor therapy in selected
tumor types (ie, multiple myeloma). Available evidence suggests that targeting the …

Introduction: Waldenström's macroglobulinemia (WM) is a rare but distinct B-cell
lymphoproliferative disorder characterized by lymphoplasmacytic bone marrow infiltration …